BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9694753)

  • 41. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels.
    Arning M; Kliche KO; Heer-Sonderhoff AH; Wehmeier A
    Mycoses; 1995; 38(11-12):459-65. PubMed ID: 8720196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
    Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
    J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.
    Krüger W; Stockschläder M; Sobottka I; Betker R; De Wit M; Kröger N; Grimm J; Arland M; Fiedler W; Erttmann R; Zander AR
    Leuk Lymphoma; 1997 Feb; 24(5-6):491-9. PubMed ID: 9086439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever.
    Spitzer TR; Creger RJ; Fox RM; Lazarus HM
    Pharmatherapeutica; 1989; 5(5):305-11. PubMed ID: 2748690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
    Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experience with community-based amphotericin B infusion therapy.
    Malani PN; Depestel DD; Riddell J; Bickley S; Klein LR; Kauffman CA
    Pharmacotherapy; 2005 May; 25(5):690-7. PubMed ID: 15899731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
    Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
    Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 51. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 53. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
    Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
    Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India.
    Jadhav MP; Shinde VM; Chandrakala S; Jijina F; Menon H; Arora B; Kurkure PA; Parikh PM; Kshirsagar NA
    Indian J Cancer; 2012; 49(1):107-13. PubMed ID: 22842177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
    Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
    Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
    Timmers GJ; Zweegman S; Simoons-Smit AM; van Loenen AC; Touw D; Huijgens PC
    Bone Marrow Transplant; 2000 Apr; 25(8):879-84. PubMed ID: 10808210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
    Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
    Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.